Egaten (triclabendazole)

Egaten (triclabendazole) is an anthelmintic indicated for the treatment of fascioliasis in patients 6 years of age and older.

Common side effects of Egaten include:

• abdominal pain,
• increased sweating,
• nausea,
• decreased appetite,
• headache,
• hives,
• diarrhea,
• vomiting,
• musculoskeletal chest pain,
• itching, and
• indigestion

• The recommended dose of Egaten is 2 doses of 10 mg/kg given 12 hours apart in patients 6 years of age and older. The 250 mg tablets are functionally scored and divisible into two equal halves of 125 mg. If the dosage cannot be adjusted exactly, round the dose upwards.
• Take Egaten orally with food. Egaten tablets can be swallowed whole or divided in half and taken with water or crushed and administered with applesauce. The crushed tablet mixed with applesauce is stable for up to 4 hours.

Effect Of Egaten On CYP2C19 Substrates

• No specific clinical drug interaction studies have been conducted for triclabendazole. However, in vitro data suggest the potential for increased plasma concentrations of CYP2C19 substrates with concomitant use of triclabendazole.
• The potential elevation in concentrations of concomitantly used CYP2C19 substrates is expected to be transient based on the short elimination half-life and short treatment duration of triclabendazole.
• For those CYP2C19 substrate drugs that require therapeutic monitoring of systemic drug exposures, if the plasma concentrations of the CYP2C19 substrates are elevated during administration of triclabendazole, recheck the plasma concentration of the CYP2C19 substrates after cessation of triclabendazole therapy.

• There are no available data on Egaten use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
• There are no data on the presence of triclabendazole in human milk, the effects on the breastfed infant, or the effects on milk production.
• Published animal data indicate that triclabendazole is detected in goat milk when administered as a single dose to one lactating animal.
• When a drug is present in animal milk, it is likely that the drug will be present in human milk.
• The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Egaten and any potential adverse effects on the breastfed infant from Egaten or from the underlying maternal condition.